About

Davos BioSciences AG (DBS) was founded as a non-profit Biotech SME and spin-off of CK-CARE (Christine Kühne – Center for Allergy Research and Education, launched by the Kühne Foundation in 2009). DBS is a subsidiary of the Medicine Campus Davos AG and belongs to the non-profit Kühne Foundation. 

We provide high-quality expertise in biobanking and laboratory services to help pharmaceutical companies in their effort to accelerate and optimize the discovery and development of new therapeutic agents and biomarkers as well as the validation of markers and products to meet regulatory requirements. Our main expertise is on inflammatory skin disorders, such as atopic dermatitis as well as other allergic diseases and disorders of the immune system. We focus our efforts particularly in the emerging field of precision medicine. 

DBS was primarily founded to manage and attend the business-related aspects of the CK-CARE registry and biobank as well as data and biomaterial from other sources. CK-CARE is one of Europe’s largest private initiatives in the field of dermatology and allergy and unifies several European key players in the field.

The CK-CARE Registry and Biorepository enable an ideal scientific reference and knowledge background for the activities of DBS which, in tight collaboration with the world-renowned Swiss Institute for Allergy and Asthma Research (SIAF), can benefit from a state-of-the-art technology platform. This helps us to rapidly address critical questions in an agile way at any stage, in the preclinical and clinical drug development programs, in post-marketing/life-cycle programs as well as in the development, validation, and regulatory qualification of biomarker-based diagnostic tests.